EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High Plasma Levels of Fibroblast Growth Factor 23 Are Associated with Increased Risk of COVID-19 in End-Stage Renal Disease Patients on Hemodialysis: Results of a Prospective Cohort

Luis Toro, Luis Michea, Alfredo Parra-Lucares, Gabriel Mendez-Valdes, Eduardo Villa, Ignacio Bravo, Catalina Pumarino, Patricia Ayala, María Eugenia Sanhueza, Ruben Torres, Leticia Elgueta, Sebastian Chavez und 2 weitere

Toxins · 2023

DOI: 10.3390/toxins15020097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Luis Toro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Hospital Clinico Universidad de Chile, Santiago 8380456, Chile. Hauptthemen laut MEDLINE: COVID-19, Kidney Failure, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigacion y Desarrollo (ANID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

End-stage renal disease (ESRD) patients are a population with high rates of COVID-19 and mortality. These patients present a low response to anti-SARS-CoV-2 immunization, which is associated with immune dysfunction. ESRD patients also present high plasma titers of Fibroblast Growth Factor 23 (FGF23), a protein hormone that reduces immune response in vivo and in vitro. Increased FGF23 levels associate with higher infection-related hospitalizations and adverse infectious outcomes. Thus, we evaluated whether ESRD patients with high FGF23 titers have an increased rate of SARS-CoV-2 infection.

Methods

We performed a prospective cohort of ESRD patients in hemodialysis who had measurements of plasma intact FGF23 in 2019. We determined COVID-19 infections, hospitalizations, and mortality between January 2020 and December 2021.

Results

We evaluated 243 patients. Age: 60.4 ± 10.8 years. Female: 120 (49.3%), diabetes: 110 (45.2%). During follow-up, 45 patients developed COVID-19 (18.5%), 35 patients were hospitalized, and 12 patients died (mortality rate: 26.6%). We found that patients with higher FGF23 levels (defined as equal or above median) had a higher rate of SARS-CoV-2 infection versus those with lower levels (18.8% versus 9.9%; Hazard ratio: 1.92 [1.03–3.56], p = 0.039). Multivariate analysis showed that increased plasma FGF23 was independently associated with SARS-CoV-2 infection and severe COVID-19.

Discussion

Our results suggest that high plasma FGF23 levels are a risk factor for developing COVID-19 in ESRD patients. These data support the potential immunosuppressive effects of high circulating FGF23 as a factor implicated in the association with worse clinical outcomes. Further data are needed to confirm this hypothesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Kidney Failure, ChronicHumansFemaleMiddle AgedAgedFibroblast Growth Factor-23Prospective StudiesFibroblast Growth FactorsSARS-CoV-2Renal Dialysis

Stichwörter der Autor:innen

COVID-19FGF23SARS-CoV-2end-stage renal diseasehemodialysisimmune responsemortality

Substanzen

Fibroblast Growth Factor-23Fibroblast Growth Factors

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Hospital Clinico Universidad de Chile, Santiago 8380456, Chile.
  • Centro de Investigación Clínica Avanzada, Hospital Clínico Universidad de Chile, Santiago 8380456, Chile.
  • Fuerza de Trabajo Anti-COVID-19 (FUTAC Team), Sociedad Chilena de Nefrología, Santiago 7500781, Chile.
  • Programa de Fisiología y Biofísica, ICBM, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
  • Division of Critical Care Medicine, Department of Medicine, Hospital Clinico Universidad de Chile, Santiago 8380456, Chile.
  • MD PhD Degree Program, Faculty of Medicine, Universidad de Chile, Santiago 8380456, Chile.

Förderung

  • Agencia Nacional de Investigacion y Desarrollo (ANID)

Zitieren

APA

Toro, L., Michea, L., Parra-Lucares, A., Mendez-Valdes, G., Villa, E., Bravo, I., Pumarino, C., Ayala, P., Sanhueza, M. E., Torres, R., Elgueta, L., Chavez, S., Rojas, V., & Alvo, M. (2023). High Plasma Levels of Fibroblast Growth Factor 23 Are Associated with Increased Risk of COVID-19 in End-Stage Renal Disease Patients on Hemodialysis: Results of a Prospective Cohort. Toxins. https://doi.org/10.3390/toxins15020097

Vancouver

Toro L, Michea L, Parra-Lucares A, Mendez-Valdes G, Villa E, Bravo I, et al. High Plasma Levels of Fibroblast Growth Factor 23 Are Associated with Increased Risk of COVID-19 in End-Stage Renal Disease Patients on Hemodialysis: Results of a Prospective Cohort. Toxins. 2023. doi:10.3390/toxins15020097

BibTeX
@article{Toro2023,
  author = {Toro, Luis and Michea, Luis and Parra-Lucares, Alfredo and Mendez-Valdes, Gabriel and Villa, Eduardo and Bravo, Ignacio and Pumarino, Catalina and Ayala, Patricia and Sanhueza, María Eugenia and Torres, Ruben and Elgueta, Leticia and Chavez, Sebastian and Rojas, Veronica and Alvo, Miriam},
  title = {High Plasma Levels of Fibroblast Growth Factor 23 Are Associated with Increased Risk of COVID-19 in End-Stage Renal Disease Patients on Hemodialysis: Results of a Prospective Cohort},
  journal = {Toxins},
  year = {2023},
  doi = {10.3390/toxins15020097}
}
Kostenlos starten →